Generic Technivie Availability
Last updated on Sep 11, 2024.
Technivie is a brand name of ombitasvir/paritaprevir/ritonavir, approved by the FDA in the following formulation(s):
TECHNIVIE (ombitasvir; paritaprevir; ritonavir - tablet;oral)
-
Manufacturer: ABBVIE
Approval date: July 24, 2015
Strength(s): 12.5MG;75MG;50MG (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Technivie. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Solid pharmaceutical dosage form
Patent 8,268,349
Issued: September 18, 2012
Inventor(s): Rosenberg Joerg & Reinhold Ulrich & Liepold Bernd & Berndl Gunther & Breitenbach Joerg & Alani Laman & Ghosh Soumojeet
Assignee(s): Abbott LaboratoriesA solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.
Patent expiration dates:
- August 25, 2024✓
- August 25, 2024
-
Solid pharmaceutical dosage form
Patent 8268349*PED
Issued: September 18, 2012
Inventor(s): Rosenberg Joerg & Reinhold Ulrich & Liepold Bernd & Berndl Gunther & Breitenbach Joerg & Alani Laman & Ghosh Soumojeet
Assignee(s): Abbott LaboratoriesA solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.
Patent expiration dates:
- February 25, 2025✓
- February 25, 2025
-
Solid pharmaceutical dosage form
Patent 8,399,015
Issued: March 19, 2013
Inventor(s): Rosenberg Joerg & Reinhold Ulrich & Liepold Bernd & Berndl Gunther & Breitenbach Joerg & Alani Laman & Ghosh Soumojeet
Assignee(s): AbbVie Inc.A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.
Patent expiration dates:
- August 25, 2024✓
- August 25, 2024
-
Solid pharmaceutical dosage form
Patent 8399015*PED
Issued: March 19, 2013
Inventor(s): Rosenberg Joerg & Reinhold Ulrich & Liepold Bernd & Berndl Gunther & Breitenbach Joerg & Alani Laman & Ghosh Soumojeet
Assignee(s): AbbVie Inc.A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.
Patent expiration dates:
- February 25, 2025✓
- February 25, 2025
-
Macrocyclic hepatitis C serine protease inhibitors
Patent 8,420,596
Issued: April 16, 2013
Inventor(s): Ku Yiyin & McDaniel Keith F. & Chen Hui-Ju & Shanley Jason P. & Kempf Dale J. & Grampovnik David J.The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
Patent expiration dates:
- April 10, 2031✓✓
- April 10, 2031
-
Macrocyclic hepatitis C serine protease inhibitors
Patent 8420596*PED
Issued: April 16, 2013
Inventor(s): Ku Yiyin & McDaniel Keith F. & Chen Hui-Ju & Shanley Jason P. & Kempf Dale J. & Grampovnik David J.The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
Patent expiration dates:
- October 10, 2031✓
- October 10, 2031
-
Macrocyclic hepatitis C serine protease inhibitors
Patent 8,642,538
Issued: February 4, 2014
Inventor(s): Ku Yiyin & McDaniel Keith F. & Chen Hui-Ju & Shanley Jason P. & Kempf Dale J. & Grampovnik David J.
Assignee(s): AbbVie, Inc.The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
Patent expiration dates:
- September 10, 2029✓✓✓
- September 10, 2029
-
Solid compositions
Patent 8,686,026
Issued: April 1, 2014
Inventor(s): Liepold Bernd & Jung Tina & Hölig Peter & Schroeder Rudolf & Sever Nancy E. & Lafountaine Justin S. & Sinclair Brent D. & Gao Yi & Wu Jianwei
Assignee(s): AbbVie Inc.The present invention features solid compositions comprising amorphous Compound I. For instance, Compound I may be formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.
Patent expiration dates:
- June 9, 2031✓
- June 9, 2031
-
Anti-viral compounds
Patent 8,691,938
Issued: April 8, 2014
Inventor(s): DeGoey David A. & Kati Warren M. & Hutchins Charles W. & Donner Pamela L. & Krueger Allan C. & Randolph John T. & Motter Christopher E. & Nelson Lissa T. & Patel Sachin V. & Matulenko Mark A. & Keddy Ryan G. & Jinkerson Tammie K. & Gao Yi & Liu Dachun & Pratt John K. & Rockway Todd W.
Assignee(s): AbbVie Inc.Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
Patent expiration dates:
- April 13, 2032✓✓
- April 13, 2032
-
Anti-viral compounds
Patent 9,006,387
Issued: April 14, 2015
Inventor(s): Wagner Rolf & Pratt John K. & Liu Dachun & Tufano Michael D. & DeGoey David A. & Kati Warren M. & Hutchins Charles W. & Donner Pamela L. & Randolph John T. & Motter Christopher E. & Nelson Lissa T. & Patel Sachin V. & Matulenko Mark A. & Keddy Ryan G. & Jinkerson Tammie K. & Rockway T
Assignee(s): AbbVie Inc.Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
Patent expiration dates:
- June 10, 2030✓
- June 10, 2030
-
Compositions and methods for treating HCV
Patent 9,044,480
Issued: June 2, 2015
Inventor(s): Pilot-Matias Tami & Gaultier Isabelle A. & Tripathi Rakesh L. & Collins Christine A. & Cohen Daniel E. & Bernstein Barry M.
Assignee(s): AbbVie Inc.The present invention features methods of using Compound I to suppress HCV mutants, treat treatment-experienced HCV patients, and treat HCV patients having non-CC IL28B rs12979860 genotype.
Patent expiration dates:
- April 10, 2031✓
- April 10, 2031
More about Technivie (ombitasvir / paritaprevir / ritonavir)
- Technivie consumer information
- Check interactions
- Compare alternatives
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: antiviral combinations
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.